Telomir Pharmaceuticals (TELO) Amortization of Deferred Charges (2023 - 2024)
Telomir Pharmaceuticals (TELO) posted Amortization of Deferred Charges of $4.3 million for Q1 2024, up 171.51% sequentially from $1.6 million in Q4 2023.
Telomir Pharmaceuticals (TELO) Amortization of Deferred Charges (2023 - 2024) Analysis & Trends
Telomir Pharmaceuticals has reported Amortization of Deferred Charges for 2 years, with the latest figure at $4.3 million in Q1 2024.
- Quarterly Amortization of Deferred Charges changed N/A year-over-year to $4.3 million in Q1 2024, while the trailing twelve-month figure through Dec 2024 was $4.3 million (changed N/A YoY) and the FY2024 annual result came in at $4.3 million, up 169.23% from the prior year.
- Amortization of Deferred Charges improved to $4.3 million in Q1 2024 per TELO's latest filing, from $1.6 million in the prior quarter.
- Over five years, Amortization of Deferred Charges peaked at $4.3 million in Q1 2024 and troughed at $13423.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Telomir Pharmaceuticals | 69.05 Mn | 69.05 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 4.34 Mn |
| Mar 31, 2024 | 4.34 Mn |
| Dec 31, 2023 | 1.60 Mn |
| Dec 31, 2023 | 1.60 Mn |
| Sep 30, 2023 | 13,423.00 |
| Sep 30, 2023 | 13,423.00 |